Status:
RECRUITING
Drinking, Acetate, and Stress
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcohol Use Disorder
Alcohol Use, Unspecified
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relat...
Detailed Description
Brain acetate consumption will be measured with a novel method called Deuterium Metabolic Imaging (DMI), in which sodium acetate that has been labeled with deuterium, a non-radioactive isotope of hydr...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Medically stable male or female, aged 18-55.
- Able to read, write and complete a multitude of self-assessments in English
- Meets DSM-5 criteria for current Alcohol Use Disorder (AUD)
- Participants who have Alcohol Use Disorder and are actively drinking must be willing to receive (at no cost) inpatient treatment for AUD for a period of up to 30 days. Participants who have been treated for an Alcohol Use Disorder and are now sober three months or longer will NOT be required to go inpatient.
Exclusion
- Subjects with any significant current medical conditions (neurological, cardiovascular, endocrine, thyroid, renal, liver), seizures (for LTS subjects only- seizures directly related to alcohol detoxification are not an exclusion) , delirium or hallucinations, or other unstable medical conditions, including HIV.
- Current DSM-5 substance use disorder (other than AUD or tobacco use disorder)
- Any metallic objects implanted in their body which would make imaging unsafe (pacemaker, etc)
- Claustrophobia, or other inability to participate in an MRI
- A positive test result at intake appointment and subsequent appointments on urine drug screens conducted for illicit drugs. (Note: participants will not be paid for study visits if they test positive for an illicit drug and will be immediately excluded from study).
- Women who are pregnant or nursing. Women who have an IUD that would make imaging unsafe.
- Recent taking of medications that may influence study outcomes (e.g., disulfiram, naltrexone, acamprosate, anticonvulsants).
- Subjects likely to exhibit clinically significant alcohol withdrawal during the study.
Key Trial Info
Start Date :
November 6 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06584448
Start Date
November 6 2024
End Date
January 1 2030
Last Update
July 28 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The Anlyan Center, 300 Cedar St.
New Haven, Connecticut, United States, 06519
2
Yale University
New Haven, Connecticut, United States, 06520